Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis
Objective: Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy in treating immune-mediated inflammatory diseases (IMIDs). However, their safety profile in terms of herpes zoster infection remains unclear. We aimed to evaluate the risk of herpes zoster associated with JA...
Saved in:
| Published in | Frontiers in pharmacology Vol. 14; p. 1241954 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Frontiers Media S.A
08.08.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Objective:
Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy in treating immune-mediated inflammatory diseases (IMIDs). However, their safety profile in terms of herpes zoster infection remains unclear. We aimed to evaluate the risk of herpes zoster associated with JAK inhibitors in patients with IMIDs.
Methods:
A systematic search of electronic databases was conducted to identify randomized controlled trials (RCTs) that evaluated the safety of JAK inhibitors in patients with IMIDs including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriasis (PsO), and psoriatic arthritis (PsA). The primary outcome of interest was the incidence of herpes zoster infection. Network meta-analysis was performed to compare the risk of herpes zoster among different JAK inhibitors and placebo.
Results:
A network meta-analysis was conducted using data from 47 RCTs including 24,142 patients. In patients with IMIDs, peficitinib 100 mg QD was associated with the highest risk of herpes zoster infection in patients with IMIDs, followed by baricitinib 4 mg QD and upadacitinib 30 mg QD. No difference in herpes zoster risk was found for other JAK inhibitors compared with placebo. Subgroup analysis indicated that higher incidence of herpes zoster was found in patients treated by baricitinib 4 mg QD, peficitinib 100 mg QD, and upadacitinib 30 mg QD only in patients with RA.
Conclusion:
Our study suggests that some JAK inhibitors, particularly peficitinib, baricitinib, and tofacitinib, are associated with a higher risk of herpes zoster infection in patients with IMIDs. |
|---|---|
| AbstractList | Objective:
Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy in treating immune-mediated inflammatory diseases (IMIDs). However, their safety profile in terms of herpes zoster infection remains unclear. We aimed to evaluate the risk of herpes zoster associated with JAK inhibitors in patients with IMIDs.
Methods:
A systematic search of electronic databases was conducted to identify randomized controlled trials (RCTs) that evaluated the safety of JAK inhibitors in patients with IMIDs including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriasis (PsO), and psoriatic arthritis (PsA). The primary outcome of interest was the incidence of herpes zoster infection. Network meta-analysis was performed to compare the risk of herpes zoster among different JAK inhibitors and placebo.
Results:
A network meta-analysis was conducted using data from 47 RCTs including 24,142 patients. In patients with IMIDs, peficitinib 100 mg QD was associated with the highest risk of herpes zoster infection in patients with IMIDs, followed by baricitinib 4 mg QD and upadacitinib 30 mg QD. No difference in herpes zoster risk was found for other JAK inhibitors compared with placebo. Subgroup analysis indicated that higher incidence of herpes zoster was found in patients treated by baricitinib 4 mg QD, peficitinib 100 mg QD, and upadacitinib 30 mg QD only in patients with RA.
Conclusion:
Our study suggests that some JAK inhibitors, particularly peficitinib, baricitinib, and tofacitinib, are associated with a higher risk of herpes zoster infection in patients with IMIDs. Objective: Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy in treating immune-mediated inflammatory diseases (IMIDs). However, their safety profile in terms of herpes zoster infection remains unclear. We aimed to evaluate the risk of herpes zoster associated with JAK inhibitors in patients with IMIDs. Methods: A systematic search of electronic databases was conducted to identify randomized controlled trials (RCTs) that evaluated the safety of JAK inhibitors in patients with IMIDs including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriasis (PsO), and psoriatic arthritis (PsA). The primary outcome of interest was the incidence of herpes zoster infection. Network meta-analysis was performed to compare the risk of herpes zoster among different JAK inhibitors and placebo. Results: A network meta-analysis was conducted using data from 47 RCTs including 24,142 patients. In patients with IMIDs, peficitinib 100 mg QD was associated with the highest risk of herpes zoster infection in patients with IMIDs, followed by baricitinib 4 mg QD and upadacitinib 30 mg QD. No difference in herpes zoster risk was found for other JAK inhibitors compared with placebo. Subgroup analysis indicated that higher incidence of herpes zoster was found in patients treated by baricitinib 4 mg QD, peficitinib 100 mg QD, and upadacitinib 30 mg QD only in patients with RA. Conclusion: Our study suggests that some JAK inhibitors, particularly peficitinib, baricitinib, and tofacitinib, are associated with a higher risk of herpes zoster infection in patients with IMIDs.Objective: Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy in treating immune-mediated inflammatory diseases (IMIDs). However, their safety profile in terms of herpes zoster infection remains unclear. We aimed to evaluate the risk of herpes zoster associated with JAK inhibitors in patients with IMIDs. Methods: A systematic search of electronic databases was conducted to identify randomized controlled trials (RCTs) that evaluated the safety of JAK inhibitors in patients with IMIDs including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriasis (PsO), and psoriatic arthritis (PsA). The primary outcome of interest was the incidence of herpes zoster infection. Network meta-analysis was performed to compare the risk of herpes zoster among different JAK inhibitors and placebo. Results: A network meta-analysis was conducted using data from 47 RCTs including 24,142 patients. In patients with IMIDs, peficitinib 100 mg QD was associated with the highest risk of herpes zoster infection in patients with IMIDs, followed by baricitinib 4 mg QD and upadacitinib 30 mg QD. No difference in herpes zoster risk was found for other JAK inhibitors compared with placebo. Subgroup analysis indicated that higher incidence of herpes zoster was found in patients treated by baricitinib 4 mg QD, peficitinib 100 mg QD, and upadacitinib 30 mg QD only in patients with RA. Conclusion: Our study suggests that some JAK inhibitors, particularly peficitinib, baricitinib, and tofacitinib, are associated with a higher risk of herpes zoster infection in patients with IMIDs. Objective: Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy in treating immune-mediated inflammatory diseases (IMIDs). However, their safety profile in terms of herpes zoster infection remains unclear. We aimed to evaluate the risk of herpes zoster associated with JAK inhibitors in patients with IMIDs.Methods: A systematic search of electronic databases was conducted to identify randomized controlled trials (RCTs) that evaluated the safety of JAK inhibitors in patients with IMIDs including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriasis (PsO), and psoriatic arthritis (PsA). The primary outcome of interest was the incidence of herpes zoster infection. Network meta-analysis was performed to compare the risk of herpes zoster among different JAK inhibitors and placebo.Results: A network meta-analysis was conducted using data from 47 RCTs including 24,142 patients. In patients with IMIDs, peficitinib 100 mg QD was associated with the highest risk of herpes zoster infection in patients with IMIDs, followed by baricitinib 4 mg QD and upadacitinib 30 mg QD. No difference in herpes zoster risk was found for other JAK inhibitors compared with placebo. Subgroup analysis indicated that higher incidence of herpes zoster was found in patients treated by baricitinib 4 mg QD, peficitinib 100 mg QD, and upadacitinib 30 mg QD only in patients with RA.Conclusion: Our study suggests that some JAK inhibitors, particularly peficitinib, baricitinib, and tofacitinib, are associated with a higher risk of herpes zoster infection in patients with IMIDs. |
| Author | He, Liyuan Xu, Qingling Yin, Yufeng |
| AuthorAffiliation | 1 Department of Gastroenterology , Wuxi Xinwu District Xinrui Hospital , Wuxi , Jiangsu , China 2 Department of Rheumatology , The First Affiliated Hospital of Soochow University , Suzhou , Jiangsu , China |
| AuthorAffiliation_xml | – name: 1 Department of Gastroenterology , Wuxi Xinwu District Xinrui Hospital , Wuxi , Jiangsu , China – name: 2 Department of Rheumatology , The First Affiliated Hospital of Soochow University , Suzhou , Jiangsu , China |
| Author_xml | – sequence: 1 givenname: Qingling surname: Xu fullname: Xu, Qingling – sequence: 2 givenname: Liyuan surname: He fullname: He, Liyuan – sequence: 3 givenname: Yufeng surname: Yin fullname: Yin, Yufeng |
| BookMark | eNp9ks9u1DAQxiNUJErpC3DykUuWOHYSmwuqKv4UKiEhOFtje9y4TezFzna1PAMPjbe7SJQDvsx4Zr6fRqPveXUSYsCqekmbFWNCvnbrEdKqbVq2oi2nsuNPqlPa96yWgrYnf-XPqvOcb5vymJSs56fVr68-35HoyIhpjZn8jHnBRCDnaDwsaMnWLyP5dPGZ-DB67ZeYckmJn-dNwHpGexjzwU0wz1D6O2J9RsiY3xAgeVeIpe4NSXjvcUsgWBJw2cZ0R2ZcoIYA0y77_KJ66mDKeH6MZ9X39---XX6sr798uLq8uK4N5_1SWz1Qp3U_MKSmRAdobMd4yzU4FL3s5VC-4NygW60RmJYN8ga6VsBQznRWXR24NsKtWic_Q9qpCF49FGK6UZDKwhMqabk00mgLpueSOdCaMSuoNbQxfYeF9fbAWm90OYbBsCSYHkEfd4If1U28V7ThZWMxFMKrIyHFHxvMi5p9NjhNEDBusmpFNwguOyHKqDiMmhRzTuiU8Us5bdyj_VSYau8I9eAItXeEOjqiSNt_pH9W_I_oN3eBwuA |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0306548 crossref_primary_10_23736_S2784_8671_24_07895_2 crossref_primary_10_1007_s13555_024_01203_2 crossref_primary_10_1093_rheumatology_keae656 crossref_primary_10_1016_j_intimp_2024_113984 crossref_primary_10_1016_j_medcle_2024_05_008 crossref_primary_10_1016_j_medcli_2024_05_007 crossref_primary_10_1038_s41584_024_01153_1 crossref_primary_10_1021_acsami_4c09087 crossref_primary_10_1007_s10067_024_07041_z crossref_primary_10_1002_jpn3_12408 crossref_primary_10_1093_rheumatology_keae096 crossref_primary_10_1093_rap_rkae127 crossref_primary_10_1016_j_jdcr_2024_06_005 crossref_primary_10_3390_biom14070739 crossref_primary_10_3390_jcm14020608 crossref_primary_10_1093_rheumatology_keae584 crossref_primary_10_55905_cuadv16n2_ed_esp_051 crossref_primary_10_7759_cureus_62372 crossref_primary_10_3390_vaccines12010085 crossref_primary_10_3390_vaccines12030252 crossref_primary_10_1002_jpn3_70024 crossref_primary_10_1111_ijd_17501 |
| Cites_doi | 10.1136/rmdopen-2022-002559 10.1016/S0140-6736(16)32537-5 10.1016/j.jval.2011.01.011 10.1093/rheumatology/kez087 10.1056/NEJMoa1310476 10.1177/1759720X20936059 10.1016/S0140-6736(19)32534-6 10.7326/0003-4819-159-4-201308200-00006 10.1136/bmj.l4898 10.1136/annrheumdis-2016-210105 10.1007/s40121-021-00567-8 10.14309/01.ajg.0000859584.83560.ef 10.1016/S0140-6736(18)31116-4 10.1001/jama.2019.9055 10.7326/M14-2385 10.1016/S0140-6736(14)62113-9 10.1136/annrheumdis-2015-208279 10.1016/s1473-3099(03)00857-0 10.3390/ijms24043391 10.1136/ard-2022-222608 10.1056/NEJMoa1109071 10.1136/annrheumdis-2019-215164 10.1056/NEJMoa1608345 10.1136/annrheumdis-2020-219601 10.1053/j.gastro.2022.08.007 10.1038/s41577-021-00603-1 10.1002/art.39473 10.1016/j.jdermsci.2017.05.004 10.1080/21645515.2020.1847582 10.1056/NEJMoa2022516 10.1136/annrheumdis-2020-218870 10.3109/14397595.2014.995875 10.1016/S0140-6736(22)01212-0 10.1016/S0140-6736(21)00666-8 10.1056/NEJMoa1606910 10.1002/art.39955 10.1056/NEJMoa1507247 10.1001/jamanetworkopen.2019.9735 10.1016/S0140-6736(19)30419-2 10.1016/S0140-6736(18)31115-2 10.1002/art.42261 10.3390/antibiotics12040757 10.1056/NEJMoa1112072 10.1002/art.39953 10.1093/infdis/jiab387 10.1056/NEJMoa1615975 10.1080/25785826.2023.2172808 10.1007/s00393-020-00750-1 10.1007/s40265-020-01349-1 10.1016/S0025-6196(11)61146-4 10.1002/art.37816 10.3390/biology11070973 10.1053/j.gastro.2020.01.001 10.3390/jcm11154459 10.1007/s00296-022-05270-6 10.1136/annrheumdis-2016-210094 10.1002/art.38949 10.1136/gutjnl-2016-312735 10.1016/j.autrev.2023.103276 10.1093/rheumatology/keaa895 10.1136/bmjopen-2015-010247 10.1136/annrheumdis-2014-206478 10.1111/1346-8138.16828 10.1016/S0140-6736(18)32483-8 10.1056/NEJMra1909094 10.1056/NEJMoa1615977 10.1136/annrheumdis-2016-210322 10.1002/jrsm.1167 10.1016/j.autrev.2021.102902 10.1016/S0140-6736(22)00581-5 10.1111/bjd.14018 10.1111/1346-8138.13956 10.1038/s41392-021-00791-1 10.1136/annrheumdis-2016-210104 10.4178/epih.e2017047 10.1371/journal.pone.0076654 10.1073/pnas.1610253113 10.1111/1756-185X.14447 10.1016/0197-2456(95)00134-4 10.1007/s10067-023-06529-4 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 Xu, He and Yin. Copyright © 2023 Xu, He and Yin. 2023 Xu, He and Yin |
| Copyright_xml | – notice: Copyright © 2023 Xu, He and Yin. – notice: Copyright © 2023 Xu, He and Yin. 2023 Xu, He and Yin |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fphar.2023.1241954 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Xu et al |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_9d49c9cbdac6493fabb33d81dc10c65e PMC10442487 10_3389_fphar_2023_1241954 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c446t-db71fbb673e1cbb6faecd53424bafe869697534aff7b2bbea3b90e40a528a7023 |
| IEDL.DBID | M48 |
| ISSN | 1663-9812 |
| IngestDate | Wed Aug 27 01:26:58 EDT 2025 Thu Aug 21 18:36:05 EDT 2025 Thu Jul 10 19:23:48 EDT 2025 Tue Jul 01 02:53:11 EDT 2025 Thu Apr 24 23:04:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c446t-db71fbb673e1cbb6faecd53424bafe869697534aff7b2bbea3b90e40a528a7023 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 Sharmistha Banerjee, UConn Health, United States Moetaza M. Soliman, Mansoura University, Egypt Edited by: Sukanya Saha, National Institute of Environmental Health Sciences (NIH), United States Reviewed by: Tarunendu Mapder, Bristol Myers Squibb, United States |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2023.1241954 |
| PQID | 2857849588 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9d49c9cbdac6493fabb33d81dc10c65e pubmedcentral_primary_oai_pubmedcentral_nih_gov_10442487 proquest_miscellaneous_2857849588 crossref_citationtrail_10_3389_fphar_2023_1241954 crossref_primary_10_3389_fphar_2023_1241954 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-08-08 |
| PublicationDateYYYYMMDD | 2023-08-08 |
| PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationTitle | Frontiers in pharmacology |
| PublicationYear | 2023 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Papp (B54) 2015; 173 Sandborn (B57) 2017; 376 Kavanaugh (B33) 2017; 76 Kivitz (B36) 2017; 69 Mease (B49) 2021; 80 Danese (B11) 2022; 399 Jadad (B32) 1996; 17 Lee (B38) 2014; 370 Panés (B53) 2017; 66 Leng (B40) 2023; 9 Olivera (B51) 2020; 158 Hoaglin (B28) 2011; 14 Takeuchi (B64) 2019; 78 Clarke (B9) 2021; 60 Kawahira (B34) 2023 Harkins (B27) 2023; 26 Hutton (B30) 2015; 162 Van Der Heijde (B69) 2022; 81 Ortega (B52) 2022; 11 Moodley (B50) 2016; 113 Loftus (B43) 2022; 10 Schett (B58) 2021; 385 Westhovens (B78) 2017; 76 Sunzini (B62) 2020; 12 Rusiñol (B55) 2023; 24 Hu (B29) 2021; 6 Van Der Heijde (B71) 2019; 394 Genovese (B20) 2019; 322 Kremer (B37) 2013; 159 Vermeire (B76) 2017; 389 Harbecke (B25) 2021; 224 Valladales-Restrepo (B68) 2023; 12 Van Valkenhoef (B74) 2016; 7 Bachelez (B2) 2015; 386 Curran (B10) 2022; 11 Yang (B80) 2023; 42 Campanaro (B6) 2021; 20 Lee (B39) 2020; 79 Van Oorschot (B73) 2021; 17 Genovese (B21); 374 Abe (B1) 2017; 44 Bechman (B3) 2019; 58 Burmester (B5) 2018; 391 Shim (B59) 2017; 39 Genovese (B19) 2018; 391 Chaimani (B7) 2013; 8 Keystone (B35) 2015; 74 Mcinnes (B46); 21 Feagan (B15) 2021; 397 Mease (B47) 2018; 392 Fleischmann (B18) 2017; 69 Harigai (B26) 2020; 80 Mease (B48) 2017; 377 Taylor (B66) 2017; 376 Fleischmann (B16) 2012; 367 Smolen (B60) 2019; 393 Dougados (B14) 2017; 76 Mcinnes (B45); 21 Benucci (B4) 2023; 22 Zhang (B81) 2017; 88 Leung (B41) 2022; 74 Van Vollenhoven (B75) 2012; 367 Deodhar (B12) 2021; 80 Deodhar (B13) 2022; 400 Genovese (B22); 68 Gialouri (B23) 2023; 43 Thomas (B67) 2004; 4 Tanaka (B65) 2015; 25 Chen (B8) 2022; 163 Van Der Heijde (B72) 2013; 65 Gladman (B24) 2017; 377 Fleischmann (B17) 2015; 67 Sampathkumar (B56) 2009; 84 Yamaoka (B79) 2023 Lin (B42) 2019; 2 Mcinnes (B44) 2021; 384 Inthout (B31) 2016; 6 Sterne (B61) 2019; 366 Takeuchi (B63) 2016; 75 Wang (B77) 2022; 11 Van Der Heijde (B70) 2017; 76 |
| References_xml | – volume: 9 start-page: e002559 year: 2023 ident: B40 article-title: Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: A phase 3, randomised, double-blind, placebo-controlled study publication-title: RMD Open doi: 10.1136/rmdopen-2022-002559 – volume: 389 start-page: 266 year: 2017 ident: B76 article-title: Clinical remission in patients with moderate-to-severe crohn's disease treated with filgotinib (the FITZROY study): Results from a phase 2, double-blind, randomised, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32537-5 – volume: 14 start-page: 429 year: 2011 ident: B28 article-title: Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR task force on indirect treatment comparisons good research practices: Part 2 publication-title: Value Health doi: 10.1016/j.jval.2011.01.011 – volume: 58 start-page: 1755 year: 2019 ident: B3 article-title: A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis publication-title: Rheumatol. Oxf. doi: 10.1093/rheumatology/kez087 – volume: 370 start-page: 2377 year: 2014 ident: B38 article-title: Tofacitinib versus methotrexate in rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1310476 – volume: 12 start-page: 1759720X20936059 year: 2020 ident: B62 article-title: JAK inhibitors and infections risk: Focus on herpes zoster publication-title: Ther. Adv. Musculoskelet. Dis. doi: 10.1177/1759720X20936059 – volume: 394 start-page: 2108 year: 2019 ident: B71 article-title: Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial publication-title: Lancet doi: 10.1016/S0140-6736(19)32534-6 – volume: 159 start-page: 253 year: 2013 ident: B37 article-title: Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial publication-title: Ann. Intern Med. doi: 10.7326/0003-4819-159-4-201308200-00006 – volume: 366 start-page: l4898 year: 2019 ident: B61 article-title: RoB 2: A revised tool for assessing risk of bias in randomised trials publication-title: Bmj doi: 10.1136/bmj.l4898 – volume: 76 start-page: 1009 year: 2017 ident: B33 article-title: Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: Results from a randomised, dose-finding study (Darwin 2) publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-210105 – volume: 11 start-page: 389 year: 2022 ident: B10 article-title: Meta-regression of herpes zoster incidence worldwide publication-title: Infect. Dis. Ther. doi: 10.1007/s40121-021-00567-8 – volume: 10 start-page: 103 year: 2022 ident: B43 article-title: Efficacy and safety of upadactinib induction therapy in patients with moderately to severely active Crohn's disease: Results from a randomized phase 3 U-EXCEL study publication-title: United Eur. Gastroenterol. J. doi: 10.14309/01.ajg.0000859584.83560.ef – volume: 391 start-page: 2513 year: 2018 ident: B19 article-title: Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(18)31116-4 – volume: 322 start-page: 315 year: 2019 ident: B20 article-title: Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial publication-title: Jama doi: 10.1001/jama.2019.9055 – volume: 162 start-page: 777 year: 2015 ident: B30 article-title: The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations publication-title: Ann. Intern Med. doi: 10.7326/M14-2385 – volume: 386 start-page: 552 year: 2015 ident: B2 article-title: Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(14)62113-9 – volume: 75 start-page: 1057 year: 2016 ident: B63 article-title: Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: A 12-week, randomised, double-blind, placebo-controlled phase IIb study publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2015-208279 – volume: 4 start-page: 26 year: 2004 ident: B67 article-title: What does epidemiology tell us about risk factors for herpes zoster? publication-title: Lancet Infect. Dis. doi: 10.1016/s1473-3099(03)00857-0 – volume: 24 start-page: 3391 year: 2023 ident: B55 article-title: Tyk2 targeting in immune-mediated inflammatory diseases publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms24043391 – volume: 81 start-page: 1515 year: 2022 ident: B69 article-title: Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: A double-blind, randomised, placebo-controlled phase 3 trial publication-title: Ann. Rheum. Dis. doi: 10.1136/ard-2022-222608 – volume: 367 start-page: 495 year: 2012 ident: B16 article-title: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1109071 – volume: 78 start-page: 1305 year: 2019 ident: B64 article-title: Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2019-215164 – volume: 376 start-page: 652 year: 2017 ident: B66 article-title: Baricitinib versus placebo or adalimumab in rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1608345 – volume: 80 start-page: 1004 year: 2021 ident: B12 article-title: Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-219601 – volume: 163 start-page: 1555 year: 2022 ident: B8 article-title: Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: A phase II study publication-title: Gastroenterology doi: 10.1053/j.gastro.2022.08.007 – volume: 21 start-page: 680 ident: B45 article-title: Immune-mediated inflammatory disease therapeutics: Past, present and future publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-021-00603-1 – volume: 68 start-page: 46 ident: B22 article-title: VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis publication-title: Arthritis Rheumatol. doi: 10.1002/art.39473 – volume: 88 start-page: 36 year: 2017 ident: B81 article-title: The efficacy and safety of tofacitinib in asian patients with moderate to severe chronic plaque psoriasis: A phase 3, randomized, double-blind, placebo-controlled study publication-title: J. Dermatol Sci. doi: 10.1016/j.jdermsci.2017.05.004 – volume: 17 start-page: 1714 year: 2021 ident: B73 article-title: A systematic literature review of herpes zoster incidence worldwide publication-title: Hum. Vaccin Immunother. doi: 10.1080/21645515.2020.1847582 – volume: 384 start-page: 1227 year: 2021 ident: B44 article-title: Trial of upadacitinib and adalimumab for psoriatic arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2022516 – volume: 80 start-page: 312 year: 2021 ident: B49 article-title: Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-218870 – volume: 25 start-page: 514 year: 2015 ident: B65 article-title: Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: A 12-week, randomized, phase 2 study publication-title: Mod. Rheumatol. doi: 10.3109/14397595.2014.995875 – volume: 400 start-page: 369 year: 2022 ident: B13 article-title: Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): A randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(22)01212-0 – volume: 397 start-page: 2372 year: 2021 ident: B15 article-title: Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): A phase 2b/3 double-blind, randomised, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(21)00666-8 – volume: 21 start-page: 680 ident: B46 article-title: Immune-mediated inflammatory disease therapeutics: Past, present and future publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-021-00603-1 – volume: 376 start-page: 1723 year: 2017 ident: B57 article-title: Tofacitinib as induction and maintenance therapy for ulcerative colitis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1606910 – volume: 69 start-page: 709 year: 2017 ident: B36 article-title: Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate publication-title: Arthritis Rheumatol. doi: 10.1002/art.39955 – volume: 374 start-page: 1243 ident: B21 article-title: Baricitinib in patients with refractory rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1507247 – volume: 2 start-page: e199735 year: 2019 ident: B42 article-title: Use of prediction intervals in network meta-analysis publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.9735 – volume: 393 start-page: 2303 year: 2019 ident: B60 article-title: Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study publication-title: Lancet doi: 10.1016/S0140-6736(19)30419-2 – volume: 391 start-page: 2503 year: 2018 ident: B5 article-title: Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(18)31115-2 – volume: 74 start-page: 1833 year: 2022 ident: B41 article-title: Recombinant zoster vaccine uptake and risk of flares among older adults with immune-mediated inflammatory diseases in the US publication-title: Arthritis and Rheumatology doi: 10.1002/art.42261 – volume: 12 start-page: 757 year: 2023 ident: B68 article-title: Pharmacological treatment of herpes zoster and factors associated with its recurrence publication-title: Antibiot. (Basel) doi: 10.3390/antibiotics12040757 – volume: 367 start-page: 508 year: 2012 ident: B75 article-title: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1112072 – volume: 69 start-page: 506 year: 2017 ident: B18 article-title: Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and No or limited prior disease-modifying antirheumatic drug treatment publication-title: Arthritis Rheumatol. doi: 10.1002/art.39953 – volume: 224 start-page: S429 year: 2021 ident: B25 article-title: Herpes zoster vaccines publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiab387 – volume: 377 start-page: 1537 year: 2017 ident: B48 article-title: Tofacitinib or adalimumab versus placebo for psoriatic arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1615975 – start-page: 1 year: 2023 ident: B79 article-title: JAK inhibitors in rheumatology publication-title: Immunol. Med. doi: 10.1080/25785826.2023.2172808 – volume: 79 start-page: 785 year: 2020 ident: B39 article-title: Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis publication-title: Z Rheumatol. doi: 10.1007/s00393-020-00750-1 – volume: 80 start-page: 1183 year: 2020 ident: B26 article-title: Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: Is expectation the root of all headache? publication-title: Drugs doi: 10.1007/s40265-020-01349-1 – volume: 84 start-page: 274 year: 2009 ident: B56 article-title: Herpes zoster (shingles) and postherpetic neuralgia publication-title: Mayo Clin. Proc. doi: 10.1016/S0025-6196(11)61146-4 – volume: 65 start-page: 559 year: 2013 ident: B72 article-title: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study publication-title: Arthritis Rheum. doi: 10.1002/art.37816 – volume: 11 start-page: 973 year: 2022 ident: B52 article-title: Immune-mediated diseases from the point of view of psychoneuroimmunoendocrinology publication-title: Biol. (Basel) doi: 10.3390/biology11070973 – volume: 158 start-page: 1554 year: 2020 ident: B51 article-title: Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.01.001 – volume: 11 start-page: 4459 year: 2022 ident: B77 article-title: Efficacy and safety of JAK inhibitors for rheumatoid arthritis: A meta-analysis publication-title: J. Clin. Med. doi: 10.3390/jcm11154459 – volume: 43 start-page: 421 year: 2023 ident: B23 article-title: Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: A systematic review of clinical trials and real-world studies publication-title: Rheumatol. Int. doi: 10.1007/s00296-022-05270-6 – volume: 76 start-page: 88 year: 2017 ident: B14 article-title: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-210094 – volume: 67 start-page: 334 year: 2015 ident: B17 article-title: A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis publication-title: Arthritis Rheumatol. doi: 10.1002/art.38949 – volume: 66 start-page: 1049 year: 2017 ident: B53 article-title: Tofacitinib for induction and maintenance therapy of crohn's disease: Results of two phase IIb randomised placebo-controlled trials publication-title: Gut doi: 10.1136/gutjnl-2016-312735 – volume: 22 start-page: 103276 year: 2023 ident: B4 article-title: JAK inhibitors and autoimmune rheumatic diseases publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2023.103276 – volume: 60 start-page: ii24 year: 2021 ident: B9 article-title: The safety of JAK-1 inhibitors publication-title: Rheumatol. Oxf. doi: 10.1093/rheumatology/keaa895 – volume: 6 start-page: e010247 year: 2016 ident: B31 article-title: Plea for routinely presenting prediction intervals in meta-analysis publication-title: BMJ Open doi: 10.1136/bmjopen-2015-010247 – volume: 74 start-page: 333 year: 2015 ident: B35 article-title: Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2014-206478 – year: 2023 ident: B34 article-title: Risk of herpes zoster according to past history in the general population: The Japanese Shozu herpes zoster study publication-title: J. Dermatol doi: 10.1111/1346-8138.16828 – volume: 392 start-page: 2367 year: 2018 ident: B47 article-title: Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): Results from a randomised, placebo-controlled, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(18)32483-8 – volume: 385 start-page: 628 year: 2021 ident: B58 article-title: Reframing immune-mediated inflammatory diseases through signature cytokine hubs publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1909094 – volume: 377 start-page: 1525 year: 2017 ident: B24 article-title: Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1615977 – volume: 76 start-page: 1340 year: 2017 ident: B70 article-title: Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, dose-ranging study publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-210322 – volume: 7 start-page: 80 year: 2016 ident: B74 article-title: Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis publication-title: Res. Synth. Methods doi: 10.1002/jrsm.1167 – volume: 20 start-page: 102902 year: 2021 ident: B6 article-title: JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2021.102902 – volume: 399 start-page: 2113 year: 2022 ident: B11 article-title: Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(22)00581-5 – volume: 173 start-page: 949 year: 2015 ident: B54 article-title: Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials publication-title: Br. J. Dermatol doi: 10.1111/bjd.14018 – volume: 44 start-page: 1228 year: 2017 ident: B1 article-title: Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial publication-title: J. Dermatol doi: 10.1111/1346-8138.13956 – volume: 6 start-page: 402 year: 2021 ident: B29 article-title: The JAK/STAT signaling pathway: From bench to clinic publication-title: Signal Transduct. Target Ther. doi: 10.1038/s41392-021-00791-1 – volume: 76 start-page: 998 year: 2017 ident: B78 article-title: Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: Results from a randomised, dose-finding study (Darwin 1) publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-210104 – volume: 39 start-page: e2017047 year: 2017 ident: B59 article-title: Network meta-analysis: Application and practice using Stata publication-title: Epidemiol. Health doi: 10.4178/epih.e2017047 – volume: 8 start-page: e76654 year: 2013 ident: B7 article-title: Graphical tools for network meta-analysis in STATA publication-title: PloS one doi: 10.1371/journal.pone.0076654 – volume: 113 start-page: 9852 year: 2016 ident: B50 article-title: Network pharmacology of JAK inhibitors publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1610253113 – volume: 26 start-page: 31 year: 2023 ident: B27 article-title: Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis publication-title: Int. J. Rheum. Dis. doi: 10.1111/1756-185X.14447 – volume: 17 start-page: 1 year: 1996 ident: B32 article-title: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? publication-title: Control Clin. Trials doi: 10.1016/0197-2456(95)00134-4 – volume: 42 start-page: 1593 year: 2023 ident: B80 article-title: Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: A systematic review and meta-analysis publication-title: Clin. Rheumatol. doi: 10.1007/s10067-023-06529-4 |
| SSID | ssj0000399364 |
| Score | 2.4769523 |
| SecondaryResourceType | review_article |
| Snippet | Objective:
Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy in treating immune-mediated inflammatory diseases (IMIDs).... Objective: Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy in treating immune-mediated inflammatory diseases (IMIDs).... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 1241954 |
| SubjectTerms | herpes zoster immune-mediated inflammatory diseases JAK inhibitors meta-analysis Pharmacology systematic review |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQT7G8NEioFxoax97Y5lYQVVUEqlAr9WZ5HEcb0WZXzfZQfgM_mpkk7W4ucOGUyHESx9_YMxN7vhHiHSYpS2swQ205hZmSmQuqylDpPOSmQhM5Gvnb9_LoTB-fz8-3Un3xnrCBHnjouH1XaRddxCrEkh5VB0SlKrKyosxjOU88-5LO23Km-jmY9W6phygZ8sLcfr1aBOb_LNQHUmnMczbRRD1h_8TKnO6R3FI6hw_Fg9FahIOhlY_EvdQ-FrsnA930zR6cbqKnuj3YhZMNEfXNE_H7R9P9hGUNVGuVOvjFAR1XEEZEUgX8FxaOD75C0y4abDjzDp1Cw0EjKeujSrgaSSEJzmW_IA_jkk73EQJseKBhiIGB0FbQDlvL4TKtQxZG1pOn4uzwy-nno2zMvpBFchHXGcEka8TSqCQjHeuQYjVXutAY6mRLV3JMrg51bbBATEGhyxMhPC9sMNTPz8ROu2zTcwFUqktllNM2aZQGnXK5lgE1SZCyOBPyFgkfR2pyzpBx4clFYfR8j55n9PyI3ky8v7tnNRBz_LX2Jwb4riaTavcFJGp-FDX_L1Gbibe34uFpEPLKSmjT8rrzhaWJj1xNa2fCTuRm8sbplbZZ9HTe5BBTp1rz4n-08aW4z9_db1G0r8TO-uo6vSazaY1v-hHyB2I-HfM priority: 102 providerName: Directory of Open Access Journals |
| Title | Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis |
| URI | https://www.proquest.com/docview/2857849588 https://pubmed.ncbi.nlm.nih.gov/PMC10442487 https://doaj.org/article/9d49c9cbdac6493fabb33d81dc10c65e |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKuXBBPMXyqIyEeqEpceyNbSSECqKqiooq1JV6izyJw0a02WWzlVh-Az-aGcfbJRIgcYrjOIkyj8yM7fmGsRfghciNhgSUoRJmUiTWySoBqVKX6gp0SdnIJ5_yo4k6Ph-fb7F1uaNIwO6PoR3Vk5osLva_f1u9RYV_QxEn2ttX9XzqCNozk_torQjC7Aa7iQ1NinoS3f3wZyZrHBClBBraxKJx6_No_vKYga0KkP4DP3S4i_I3s3R4h92O_iQ_6AXgLtvy7T22e9oDUq_2-Nkmv6rb47v8dANVvbrPfn5uuq98VnMcNfcd_0EpHwvuIs98xWmelh8ffORNO22godo82OQNpZX4JOSd0DCkHIrWZViy53HRp3vNHd8gRfM-S4a7tuJtv_mcX_qlS1zERXnAJocfzt4fJbE-Q1JiELlMkJGiBsi19KLEY-18WY2lyhS42pvc5pS1q1xda8gAvJNgU48yMM6M00jnh2y7nbX-EePYq3KppVXGKxAarLSpEg4Uypg0MGJizYmijODlVEPjosAghrhXBO4VxL0icm_EXl7fM--hO_45-h0x-HokwW6HjtniSxG1uLCVsqUtoXJljnJdOwApK3T5S5GW-diP2PO1eBSoprT24lo_u-qKzOCvEYNRY0bMDORm8MbhlbaZBsBvDJmRqEY__q8vesJu0WnYrWiesu3l4so_Qw9qCTth5mEnKMcvZTkfLQ |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+herpes+zoster+associated+with+JAK+inhibitors+in+immune-mediated+inflammatory+diseases%3A+a+systematic+review+and+network+meta-analysis&rft.jtitle=Frontiers+in+pharmacology&rft.au=Xu%2C+Qingling&rft.au=He%2C+Liyuan&rft.au=Yin%2C+Yufeng&rft.date=2023-08-08&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=14&rft_id=info:doi/10.3389%2Ffphar.2023.1241954&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fphar_2023_1241954 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |